News

RegeneRx Biopharmaceuticals announces that its ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops did not meet its primary outcome measures.

According to a national study, serious vision issues among older Americans have dropped sharply, with the greatest improvement found among women, individuals over 85 and Black or Hispanic seniors.

Investigators continue to break new ground, giving hope to patients, physicians.

Physician provides contemporary perspective and pearls to guide ophthalmologists.

Researchers at the Royal College of Ophthalmologists offer guidance on the impact of treatment delays in crosslinking (CXL) amid COVID-19 on patients with keratoconus.

Visus Therapeutics announced today that FDA has approved its Investigational New Drug Application (IND) to move forward with the clinical development program for BRIMOCHOL

Investigators observe dramatic decrease in treatment burden seen in OPTIC study.

Check out the latest cartoon!

A supraciliary minimally invasive glaucoma procedure may offer a valuable bleb-free treatment option for patients with glaucoma that requires low target pressures.

Practice and preparation are key for mastering the procedure.

One surgeon shares the early results of his experience using the new TECNIS Eyhance and TECNIS Eyhance Toric II IOLs in performing the first post-FDA-approved cases in the U.S.

Patients who are at an increased risk for vision loss from lapses in care have frequently expressed concerns about the impact of the pandemic on their ability to receive timely care.

Investigators set out to determine if treatment crosses blood-retina barrier.

Technology helps physicians understand normal and abnormal macular anatomy.

The Lighthouse Guild is raising public awareness about the visually impaired, a group that has been passed over for early access to vaccinations.

Phakic option provides hope to patients who are not candidates for laser vision correction.

Graybug Vision, Inc. has reported preliminary topline data from a 12-month treatment phase of its Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet AMD.

A Canadian artificial cornea clinical trial has been enhanced by a remote, real-time 3D HD video training solution.

Physician presents pearls for effective use, leading to positive outcomes for patients.

The study will evaluate the safety and tolerability of the R:GEN laser in patients with early-stage age-related macular degeneration.

Investigators at Rokote Laboratories Finland Ltd. say they selected the nasal route of delivery because the virus is transmitted through the airways, and they claim that nasal administration may induce a wider immune response than intramuscular administration.

Transient sensory-motor abnormalities are often common.

Investigators suggest that SARS-CoV-2 may diffuse from the ocular surfaces to the patient’s body, and use of a conjunctival swab may be another method of diagnosing the virus.

Physicians should evaluate which options best meet the needs of their practices.

Citing an unstable supply chain, Pfizer is discontinuing the ophthalic drops.

Treatment may facilitate sight in end-stage retinitis pigmentosa.

George Marcellino, vice president of Iridex, is being remembered by colleagues as a man of substance.

Topcon Corp. will purchase exclusive rights to distribute Iridex Corp.’s retina and glaucoma products, while also acquiring a common equity stake in the company. Iridex will acquire Topcon’s PASCAL product line.